ĚÇĐÄvlog

Object moved to here.

Diagnosis and Treatment of Parkinson Disease: A Review | Movement Disorders | JAMA | ĚÇĐÄvlog

ĚÇĐÄvlog

[Skip to Navigation]
Sign In
1.
GBD 2016 Parkinson’s Disease Collaborators. ĚýGlobal, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.ĚýĚýł˘˛ą˛Ôł¦±đłŮ Neurol. 2018;17(11):939-953. doi:
2.
Marras ĚýC, Beck ĚýJC, Bower ĚýJH, Ěýet al; Parkinson’s Foundation P4 Group. ĚýPrevalence of Parkinson’s disease across North America.ĚýĚýNPJ Parkinsons Dis. 2018;4:21. doi:
3.
Kouli ĚýA, Torsney ĚýKM, Kuan ĚýWL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker ĚýTB, Greenland ĚýJC, eds. ĚýParkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane, Australia: Codon Publications; 2018. . Accessed September 6, 2019. doi:
4.
International Parkinson and Movement Disorder Society. ĚýEvidence Based Medicine Publications.. Accessed November 14, 2019.
5.
Wilczynski ĚýNL, McKibbon ĚýKA, Walter ĚýSD, Garg ĚýAX, Haynes ĚýRB. ĚýMEDLINE clinical queries are robust when searching in recent publishing years.ĚýĚýJ Am Med Inform Assoc. 2013;20(2):363-368. doi:
6.
US National Library of Medicine. ĚýSearch strategy used to create the PubMed systematic reviews filter.. Updated December 2018. Accessed September 6, 2019.
7.
Braak ĚýH, Del Tredici ĚýK, RĂĽb ĚýU, de Vos ĚýRA, Jansen Steur ĚýEN, Braak ĚýE. ĚýStaging of brain pathology related to sporadic Parkinson’s disease.ĚýĚýNeurobiol Aging. 2003;24(2):197-211. doi:
8.
Pasquini ĚýJ, Ceravolo ĚýR, Qamhawi ĚýZ, Ěýet al. ĚýProgression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study.ĚýĚýµţ°ů˛ąľ±˛Ô. 2018;141(3):811-821. doi:
9.
Factor ĚýSA, McDonald ĚýWM, Goldstein ĚýFC. ĚýThe role of neurotransmitters in the development of Parkinson’s disease–related psychosis.ĚýĚýEur J Neurol. 2017;24(10):1244-1254. doi:
10.
Schapira ĚýAHV, Chaudhuri ĚýKR, Jenner ĚýP. ĚýNon-motor features of Parkinson disease.ĚýĚýNat Rev Neurosci. 2017;18(7):435-450. doi:
11.
Maillet ĚýA, Krack ĚýP, LhommĂ©e ĚýE, Ěýet al. ĚýThe prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease.ĚýĚýµţ°ů˛ąľ±˛Ô. 2016;139(Pt 9):2486-2502. doi:
12.
Morris ĚýR, Martini ĚýDN, Madhyastha ĚýT, Ěýet al. ĚýOverview of the cholinergic contribution to gait, balance and falls in Parkinson’s disease.ĚýĚýParkinsonism Relat Disord. 2019;63:20-30. doi:
13.
Chaudhuri ĚýKR, Prieto-Jurcynska ĚýC, Naidu ĚýY, Ěýet al. ĚýThe nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire.ĚýĚýMov Disord. 2010;25(6):704-709. doi:
14.
Berg ĚýD, Postuma ĚýRB, Adler ĚýCH, Ěýet al. ĚýMDS research criteria for prodromal Parkinson’s disease.ĚýĚýMov Disord. 2015;30(12):1600-1611. doi:
15.
Galbiati ĚýA, Verga ĚýL, Giora ĚýE, Zucconi ĚýM, Ferini-Strambi ĚýL. ĚýThe risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies.ĚýĚýSleep Med Rev. 2019;43:37-46. doi:
16.
Howell ĚýMJ, Schenck ĚýCH. ĚýRapid eye movement sleep behavior disorder and neurodegenerative disease.ĚýĚýJAMA Neurol. 2015;72(6):707-712. doi:
17.
Fearnley ĚýJM, Lees ĚýAJ. ĚýAgeing and Parkinson’s disease: substantia nigra regional selectivity.ĚýĚýµţ°ů˛ąľ±˛Ô. 1991;114(Pt 5):2283-2301. doi:
18.
Hughes ĚýAJ, Daniel ĚýSE, Blankson ĚýS, Lees ĚýAJ. ĚýA clinicopathologic study of 100 cases of Parkinson’s disease.ĚýĚýArch Neurol. 1993;50(2):140-148. doi:
19.
Postuma ĚýRB, Berg ĚýD, Stern ĚýM, Ěýet al. ĚýMDS clinical diagnostic criteria for Parkinson’s disease.ĚýĚýMov Disord. 2015;30(12):1591-1601. doi:
20.
Ahlskog ĚýJE, Muenter ĚýMD. ĚýFrequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.ĚýĚýMov Disord. 2001;16(3):448-458. doi:
21.
Suwijn ĚýSR, van Boheemen ĚýCJ, de Haan ĚýRJ, Tissingh ĚýG, Booij ĚýJ, de Bie ĚýRM. ĚýThe diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review.ĚýĚýEJNMMI Res. 2015;5:12. doi:
22.
Isaacson ĚýSH, Fisher ĚýS, Gupta ĚýF, Ěýet al. ĚýClinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.ĚýĚýExpert Rev Neurother. 2017;17(3):219-225. doi:
23.
Bajaj ĚýN, Hauser ĚýRA, Grachev ĚýID. ĚýClinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.ĚýĚýJ Neurol Neurosurg Psychiatry. 2013;84(11):1288-1295. doi:
24.
Prange ĚýS, Metereau ĚýE, Thobois ĚýS. ĚýStructural imaging in Parkinson’s disease: new developments.ĚýĚýCurr Neurol Neurosci Rep. 2019;19(8):50. doi:
25.
Burciu ĚýRG, Ofori ĚýE, Archer ĚýDB, Ěýet al. ĚýProgression marker of Parkinson’s disease: a 4-year multi-site imaging study.ĚýĚýµţ°ů˛ąľ±˛Ô. 2017;140(8):2183-2192. doi:
26.
Orimo ĚýS, Suzuki ĚýM, Inaba ĚýA, Mizusawa ĚýH. Ěý123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.ĚýĚýParkinsonism Relat Disord. 2012;18(5):494-500. doi:
27.
Fereshtehnejad ĚýSM, Postuma ĚýRB. ĚýSubtypes of Parkinson’s disease: what do they tell us about disease progression?ĚýĚýCurr Neurol Neurosci Rep. 2017;17(4):34. doi:
28.
Thenganatt ĚýMA, Jankovic ĚýJ. ĚýParkinson disease subtypes.ĚýĚýJAMA Neurol. 2014;71(4):499-504. doi:
29.
Fereshtehnejad ĚýSM, Zeighami ĚýY, Dagher ĚýA, Postuma ĚýRB. ĚýClinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression.ĚýĚýµţ°ů˛ąľ±˛Ô. 2017;140(7):1959-1976. doi:
30.
Lawton ĚýM, Ben-Shlomo ĚýY, May ĚýMT, Ěýet al. ĚýDeveloping and validating Parkinson’s disease subtypes and their motor and cognitive progression.ĚýĚýJ Neurol Neurosurg Psychiatry. 2018;89(12):1279-1287. doi:
31.
van Rooden ĚýSM, Colas ĚýF, MartĂ­nez-MartĂ­n ĚýP, Ěýet al. ĚýClinical subtypes of Parkinson’s disease.ĚýĚýMov Disord. 2011;26(1):51-58. doi:
32.
De Pablo-Fernández ĚýE, Lees ĚýAJ, Holton ĚýJL, Warner ĚýTT. ĚýPrognosis and neuropathologic correlation of clinical subtypes of Parkinson disease.ĚýĚýJAMA Neurol. 2019;76(4):470-479. doi:
33.
Macleod ĚýAD, Taylor ĚýKS, Counsell ĚýCE. ĚýMortality in Parkinson’s disease: a systematic review and meta-analysis.ĚýĚýMov Disord. 2014;29(13):1615-1622. doi:
34.
Hely ĚýMA, Reid ĚýWGJ, Adena ĚýMA, Halliday ĚýGM, Morris ĚýJGL. ĚýThe Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years.ĚýĚýMov Disord. 2008;23(6):837-844. doi:
35.
Moscovich ĚýM, Boschetti ĚýG, Moro ĚýA, Teive ĚýHAG, Hassan ĚýA, Munhoz ĚýRP. ĚýDeath certificate data and causes of death in patients with parkinsonism.ĚýĚýParkinsonism Relat Disord. 2017;41:99-103. doi:
36.
Pennington ĚýS, Snell ĚýK, Lee ĚýM, Walker ĚýR. ĚýThe cause of death in idiopathic Parkinson’s disease.ĚýĚýParkinsonism Relat Disord. 2010;16(7):434-437. doi:
37.
Chou ĚýKL, Stacy ĚýM, Simuni ĚýT, Ěýet al. ĚýThe spectrum of “off” in Parkinson’s disease: what have we learned over 40 years?ĚýĚýParkinsonism Relat Disord. 2018;51:9-16. doi:
38.
Cilia ĚýR, Akpalu ĚýA, Sarfo ĚýFS, Ěýet al. ĚýThe modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa.ĚýĚýµţ°ů˛ąľ±˛Ô. 2014;137(Pt 10):2731-2742. doi:
39.
Espay ĚýAJ, Morgante ĚýF, Merola ĚýA, Ěýet al. ĚýLevodopa-induced dyskinesia in Parkinson disease: current and evolving concepts.ĚýĚýAnn Neurol. 2018;84(6):797-811. doi:
40.
Turcano ĚýP, Mielke ĚýMM, Bower ĚýJH, Ěýet al. ĚýLevodopa-induced dyskinesia in Parkinson disease: a population-based cohort study.ĚýĚý±·±đłÜ°ů´Ç±ô´Ç˛µ˛â. 2018;91(24):e2238-e2243. doi:
41.
Williams-Gray ĚýCH, Mason ĚýSL, Evans ĚýJR, Ěýet al. ĚýThe CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort.ĚýĚýJ Neurol Neurosurg Psychiatry. 2013;84(11):1258-1264. doi:
42.
Luquin ĚýMR, Kulisevsky ĚýJ, Martinez-Martin ĚýP, Mir ĚýP, Tolosa ĚýES. ĚýConsensus on the definition of advanced Parkinson’s disease: a neurologists-based Delphi study (CEPA Study).ĚýĚýParkinsons Dis. 2017;2017:4047392. doi:
43.
Fox ĚýSH, Katzenschlager ĚýR, Lim ĚýSY, Ěýet al; Movement Disorder Society Evidence-Based Medicine Committee. ĚýInternational Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease.ĚýĚýMov Disord. 2018;33(8):1248-1266. doi:
44.
Espay ĚýAJ, Lang ĚýAE. ĚýCommon myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice.ĚýĚýJAMA Neurol. 2017;74(6):633-634. doi:
45.
Gray ĚýR, Ives ĚýN, Rick ĚýC, Ěýet al; PD Med Collaborative Group. ĚýLong-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.ĚýĚýł˘˛ą˛Ôł¦±đłŮ. 2014;384(9949):1196-1205. doi:
46.
Garcia-Ruiz ĚýPJ, Martinez Castrillo ĚýJC, Alonso-Canovas ĚýA, Ěýet al. ĚýImpulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study.ĚýĚýJ Neurol Neurosurg Psychiatry. 2014;85(8):840-844. doi:
47.
Rabinak ĚýCA, Nirenberg ĚýMJ. ĚýDopamine agonist withdrawal syndrome in Parkinson disease.ĚýĚýArch Neurol. 2010;67(1):58-63. doi:
48.
Pondal ĚýM, Marras ĚýC, Miyasaki ĚýJ, Ěýet al. ĚýClinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.ĚýĚýJ Neurol Neurosurg Psychiatry. 2013;84(2):130-135. doi:
49.
Pessoa ĚýRR, Moro ĚýA, Munhoz ĚýRP, Teive ĚýHAG, Lees ĚýAJ. ĚýApomorphine in the treatment of Parkinson’s disease: a review.ĚýĚýArq Neuropsiquiatr. 2018;76(12):840-848. doi:
50.
LeWitt ĚýPA, Hauser ĚýRA, Pahwa ĚýR, Ěýet al; SPAN-PD Study Investigators. ĚýSafety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial.ĚýĚýł˘˛ą˛Ôł¦±đłŮ Neurol. 2019;18(2):145-154. doi:
51.
Pahwa ĚýR, Tanner ĚýCM, Hauser ĚýRA, Ěýet al. ĚýADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial.ĚýĚýJAMA Neurol. 2017;74(8):941-949. doi:
52.
Vertical Pharmaceuticals. ĚýOsmolex ER prescribing information. 2018. . Accessed July 29, 2019.
53.
Mak ĚýMK, Wong-Yu ĚýIS, Shen ĚýX, Chung ĚýCL. ĚýLong-term effects of exercise and physical therapy in people with Parkinson disease.ĚýĚýNat Rev Neurol. 2017;13(11):689-703. doi:
54.
Chung ĚýCL, Thilarajah ĚýS, Tan ĚýD. ĚýEffectiveness of resistance training on muscle strength and physical function in people with Parkinson’s disease: a systematic review and meta-analysis.ĚýĚýClin Rehabil. 2016;30(1):11-23. doi:
55.
Mehrholz ĚýJ, Kugler ĚýJ, Storch ĚýA, Pohl ĚýM, Hirsch ĚýK, Elsner ĚýB. ĚýTreadmill training for patients with Parkinson disease: an abridged version of a Cochrane Review.ĚýĚýEur J Phys Rehabil Med. 2016;52(5):704-713.
56.
Zhang ĚýS, Liu ĚýD, Ye ĚýD, Li ĚýH, Chen ĚýF. ĚýCan music-based movement therapy improve motor dysfunction in patients with Parkinson’s disease? systematic review and meta-analysis.ĚýĚýNeurol Sci. 2017;38(9):1629-1636. doi:
57.
Lötzke ĚýD, Ostermann ĚýT, BĂĽssing ĚýA. ĚýArgentine tango in Parkinson disease—a systematic review and meta-analysis.ĚýĚýBMC Neurol. 2015;15:226. doi:
58.
Yang ĚýY, Li ĚýXY, Gong ĚýL, Zhu ĚýYL, Hao ĚýYL. ĚýTai Chi for improvement of motor function, balance and gait in Parkinson’s disease: a systematic review and meta-analysis.ĚýĚýPLoS One. 2014;9(7):e102942. doi:
59.
Tomlinson ĚýCL, Patel ĚýS, Meek ĚýC, Ěýet al. ĚýPhysiotherapy versus placebo or no intervention in Parkinson’s disease.ĚýĚýCochrane Database Syst Rev. 2013;9(9):CD002817. doi:
60.
Factor ĚýSA, Bennett ĚýA, Hohler ĚýAD, Wang ĚýD, Miyasaki ĚýJM. ĚýQuality improvement in neurology: Parkinson disease update quality measurement set: executive summary.ĚýĚý±·±đłÜ°ů´Ç±ô´Ç˛µ˛â. 2016;86(24):2278-2283. doi:
61.
Shulman ĚýLM, Gruber-Baldini ĚýAL, Anderson ĚýKE, Fishman ĚýPS, Reich ĚýSG, Weiner ĚýWJ. ĚýThe clinically important difference on the Unified Parkinson's Disease Rating Scale.ĚýĚýArch Neurol. 2010;67(1):64-70. doi:
62.
Bratsos ĚýS, Karponis ĚýD, Saleh ĚýSN. ĚýEfficacy and safety of deep brain stimulation in the treatment of parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials.ĚýĚý°äłÜ°ů±đłÜ˛ő. 2018;10(10):e3474. doi:
63.
Bond ĚýAE, Shah ĚýBB, Huss ĚýDS, Ěýet al. ĚýSafety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial.ĚýĚýJAMA Neurol. 2017;74(12):1412-1418. doi:
64.
Moro ĚýE, SchĂĽpbach ĚýM, Wächter ĚýT, Ěýet al. ĚýReferring Parkinson’s disease patients for deep brain stimulation: a RAND/UCLA appropriateness study.ĚýĚýJ Neurol. 2016;263(1):112-119. doi:
65.
Okun ĚýMS, Fernandez ĚýHH, Pedraza ĚýO, Ěýet al. ĚýDevelopment and initial validation of a screening tool for Parkinson disease surgical candidates.ĚýĚý±·±đłÜ°ů´Ç±ô´Ç˛µ˛â. 2004;63(1):161-163. doi:
66.
Wächter ĚýT, MĂ­nguez-Castellanos ĚýA, Valldeoriola ĚýF, Herzog ĚýJ, Stoevelaar ĚýH. ĚýA tool to improve pre-selection for deep brain stimulation in patients with Parkinson’s disease.ĚýĚýJ Neurol. 2011;258(4):641-646. doi:
67.
Wang ĚýL, Li ĚýJ, Chen ĚýJ. ĚýLevodopa-carbidopa intestinal gel in Parkinson’s disease: a systematic review and meta-analysis.ĚýĚýFront Neurol. 2018;9:620. doi:
68.
Wirdefeldt ĚýK, Odin ĚýP, Nyholm ĚýD. ĚýLevodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review.ĚýĚýCNS Drugs. 2016;30(5):381-404. doi:
69.
Seppi ĚýK, Ray Chaudhuri ĚýK, Coelho ĚýM, Ěýet al; the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. ĚýUpdate on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review.ĚýĚýMov Disord. 2019;34(2):180-198. doi:
70.
Emre ĚýM, Aarsland ĚýD, Albanese ĚýA, Ěýet al. ĚýRivastigmine for dementia associated with Parkinson’s disease.ĚýĚýN Engl J Med. 2004;351(24):2509-2518. doi:
71.
Weintraub ĚýD, Chiang ĚýC, Kim ĚýHM, Ěýet al. ĚýAssociation of antipsychotic use with mortality risk in patients with parkinson disease.ĚýĚýJAMA Neurol. 2016;73(5):535-541. doi:
72.
Iketani ĚýR, Kawasaki ĚýY, Yamada ĚýH. ĚýComparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson’s disease: a systematic review and Bayesian network meta-analysis.ĚýĚýBiol Pharm Bull. 2017;40(11):1976-1982. doi:
73.
Cummings ĚýJ, Isaacson ĚýS, Mills ĚýR, Ěýet al. ĚýPimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial.ĚýĚýł˘˛ą˛Ôł¦±đłŮ. 2014;383(9916):533-540. doi:
74.
Elbers ĚýRG, Verhoef ĚýJ, van Wegen ĚýEE, Berendse ĚýHW, Kwakkel ĚýG. ĚýInterventions for fatigue in Parkinson’s disease.ĚýĚýCochrane Database Syst Rev. 2015;10(10):CD010925.
75.
Barboza ĚýJL, Okun ĚýMS, Moshiree ĚýB. ĚýThe treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease.ĚýĚýExpert Opin Pharmacother. 2015;16(16):2449-2464. doi:
76.
Srivanitchapoom ĚýP, Pandey ĚýS, Hallett ĚýM. ĚýDrooling in Parkinson’s disease: a review.ĚýĚýParkinsonism Relat Disord. 2014;20(11):1109-1118. doi:
77.
Boersma ĚýI, Miyasaki ĚýJ, Kutner ĚýJ, Kluger ĚýB. ĚýPalliative care and neurology: time for a paradigm shift.ĚýĚý±·±đłÜ°ů´Ç±ô´Ç˛µ˛â. 2014;83(6):561-567. doi:
78.
Schenkman ĚýM, Moore ĚýCG, Kohrt ĚýWM, Ěýet al. ĚýEffect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial.ĚýĚýJAMA Neurol. 2018;75(2):219-226. doi:
Views 118,287
Review
ąó±đ˛ú°ůłÜ˛ą°ů˛âĚý11, 2020

Diagnosis and Treatment of Parkinson Disease: A Review

Author Affiliations
  • 1Department of Neurology, University of Florida College of Medicine, Gainesville
  • 2Fixel Institute for Neurologic Diseases, University of Florida, Gainesville
JAMA. 2020;323(6):548-560. doi:10.1001/jama.2019.22360
Abstract

ImportanceĚý Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease–like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease.

ObservationsĚý Diagnosis of Parkinson disease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinson disease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16% of individuals with Parkinson disease) have prominent early motor and nonmotor symptoms, poor response to medication, and faster disease progression. Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression. Other individuals have an intermediate subtype. For all patients with Parkinson disease, treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. No disease-modifying pharmacologic treatments are available. Dopamine-based therapies typically help initial motor symptoms. Nonmotor symptoms require nondopaminergic approaches (eg, selective serotonin reuptake inhibitors for psychiatric symptoms, cholinesterase inhibitors for cognition). Rehabilitative therapy and exercise complement pharmacologic treatments. Individuals experiencing complications, such as worsening symptoms and functional impairment when a medication dose wears off (“off periods”), medication-resistant tremor, and dyskinesias, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation. Palliative care is part of Parkinson disease management.

Conclusions and RelevanceĚý Parkinson disease is a heterogeneous disease with rapidly and slowly progressive forms. Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise and physical, occupational, and speech therapies). Approaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremor, worsening symptoms when the medication wears off, and dyskinesias.

×